Drugs / Auto CAR-T
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04665063 | Oct 2020 → Oct 2023 | Hodgkins lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| — | NCT04665076 | Oct 2020 → Oct 2023 | plasma cell neoplasm | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| — | NCT04666168 | Oct 2020 → Oct 2023 | non-Hodgkin lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| — | NCT04610125 | Jun 2020 → Jun 2023 | leukemia, lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Auto CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04665063 ↗ |
| Modality | Cell therapy | “Auto CAR-T cell injection” NCT04610125 ↗ |
| Target | CD19 | “CD19-directed chimeric antigen receptor T (CAR-T) cell therapy” PMID 36275715 ↗ Oct 2022 |